Member Info for Indiscipline

This story on Bloomberg. Defo CF must be talking with the Chinese. Very much for their own in-house use it seems.

Will be interesting to see what comes of it.

It would be something to contact IR about. As shareholders we are perfectly entitled to ask whether this relates to ORPH.
These are pertinent questions and well dug up earache.

If enough question then this will be addressed quickly. CF has worked hard to get this company turned round. He would not want anything that stirs up antagonism hitting ORPH. Likely that this is not a direct relation to company but questioning never hurts.

Before we start going in a frenzy about the SPAC investment I think we should take a minute to just consider.

Has CF acted honourably so far. I would say yes. Has not taken huge salary, has not stuffed his package with options he never paid for. Ensures the team buy stock on open market.

If and that is a big, if Imutex were to go in a SPAC it would be done fairly and for the benefit of shareholders and the actual product. There are some bloody awful SPAC's but there are some that are equitable and well run.

Before we go into overdrive I would on previous behaviour give CF very much the benefit of the doubt. Secondly if he sold off a non-core asset for a song and spun it off, he would crater the majority of his stock in Open Orphan, making the entire excercise of enriching himself completely counterproductive.

We have not had some news for a while and it is understandable a certain stir craziness kicks in. But let's just excercise some caution.

To be fair to D-Ramper he has kind of been open on the need for further raise when he did the previous one. He got cornered into that some saw as Andrew Scott interviewed him on Proactive. But he was straight up about it.

Raises are not always negative but can be seen as hugely positive and a sign of growth. The market at present saw "extended sales cycle" and did not see growth. I was impressed when some fanboys saw those words as a positive, as something larger rather than smaller always being good.

The clue with all this is, have we seen D-Ramper out the bunker after figures promoting himself, as he so enjoyed in our all conquering phase? Hopefully when there are a series of successes we will see that beautiful baby face of JD glinting in the
studio sunlight.

Our little mole has been in his hole now for nearly eighteen months..

At most we are three to four weeks away from some serious news hitting. He may drop in a contract in the meantime to maintain price. He's been sorting out terms with a bunch of companies and now we got ethics approval it is crossing the t's time.

WE are just waiting for the starting gun.

Once we get it it will all be at once. Like buses they come in a pack.

We don't seem to have Invesco jamming the bid so that is a plus for investors. They are allowing the pattern to tighten, volatility is contracting which is a very positive sign, price wise. Those who want out are out and the buyers are not selling even when the price was moving a little down earlier.

Great stuff you gave us Wonder. Like you I can be patient as better deals are beginning to present themselves in our asstes.
The criticism was that CF was not developing assets as in our data and just looking for the one off sale to a company. We now have a changed mindset and new opportunities. Deals with CF will create new deals and markets.

We had larger volume as Invesco were on the sell. One decent piece of news and this breaks out and we are not that far off that. Right now we are surfers waiting for the next wave. It is the time when we all get a little anxious. But for risk reward, we are a share in the top percentile, in my view. Next three to six months will show the radical transformation of this company and it's price.

The deals are complicated deals and the perspective on them is changing as they grow in importance. So they may take more time to drop. If you look at Imutex it is getting sexier the drug by the minute. Also has to work with third parties. But the package on Conserv he suggested looks improved and the deal should be too.

His view on the value of the data is now changing. I think as he was new to this area of the market he did not know the true scale of the opportunity. He is probably researching hard looking at the other companies and seeing how all of pharma is zeroing on in this area and realising the size of the market. Livongo got bought for a hefty multiple by Teledoc on the data.
He is talking of a stand alone company, if he can build one of the key databases in this area with some shrewd dealmaking this can create a value opportunity that is eye watering for shareholders. CF is one hell of a deal maker from what we see.

These are potentially huge areas I am glad he is taking his time. We are getting a rerating when he gives figures mid April at latest. He is going to walk the brokers through figures for this year before, I am sure. Just on increased capacity we get a significant re-rating.

As stated in Reminisces of a Stock Operator: "It was not my doing that made me the serious money it was my sitting. Got that". To sit tight and let a secular bull move play out transforms the account. Livermore smashed that point home.

Valuation is elastic. Around 3 times is the general rule of thumb or PE around 12-15. As both are going to be ramping up in a significant way over the next 6-12 months you should do very nicely - that is outside of the sale of non core assets.

The market is a demand and supply system. What really matters is the liquidity being pumped into the share. Again I believe that once elements start kicking in we should have another expansion of demand aiding price. Also if the stock goes to Nasdaq that should significantly increase price.

All these elements are reasons why we have been aggressive in accumulation of stock.

After their 200k stock sales they ate well washed down with a nice Petrus. As for Anzu following BIDS is breadcrumbs only extensive increase in sales would suggest that to be true.

BIDS stated that they will be looking at an extended sales cycle that is not telling the market we have a large ramp up in sales. What it does tell the market is with a large headcount be ready for a decent dilution.

The share price tells you what the market view is at present. May change in two years ... Competition is tough and Draper has a lot to deliver on. Especially when you state that you can be larger than Trade Desk. Not being greedy I would be happy for a quarter of Tradedesk's market cap.

Screenshot the price now and look at it in 3-4 months when results and some non core assets hit. Just off results and trading update this will rerate significantly.

By April we have a very different animal. Cf has to take some time on the non- core asset elements as they are worth the microcap of the company each and more.

There was supposed to be an MS trial kickin in , in January. We all know how that has gone. It has just gone off the calendar.
Still we are going to get a DR K call where investors will be given another group of missed deadlines.

Tech great, Bod's attitude towards shareholders is a fat middle finger at present. The additions were great but gone cold again.

If it gets Invesco out quickly then all the better. They are one of the worst performing funds to be free of them is great.
Once they are out and we have sticky fingers this shoots with the smallest bit of news.

Could it be anything else.

I would say there is no better centre back pairing than Dier and Sanchez for unwavering consistency. You get the same standard every week.

Believe Davison Sanchez will knock in a hat trick this week. How about that for belief.

A little light hearted banter not a bad thing for this board to do. We are due on the markets a pullback so there will be a fair whack of volatility hitting. Hopefully with investors here we should be insulated more than other stock.

Invesco I imaging are working through their stack. The volume in stock is picking up meaning they should be gone sooner now, while others are still accumulating.

Also non core asset news can drop any day now so lightening up could be a loss leader.

Standard Spread Betting practise. The hedging must be costing them a fortune. As we saw with Gamestop they can perform all manner of nefarious activity on the side.

He has been careful not to publish contract prices. One confidentiality for client.
Two and most importantly allows him to charge more as demand keeps increasing.

The fact is we can't have a dispassionate balanced conversation about JD as the two camps those for and against move further and further apart.

JD has done some great things around the build out but some not so great things around promotion and management. This is the chasm that creates the two groups and the perspectives we have. What fell between them was the share price.

I hope there is a time when Bottom and Helx can agree. That would be as the stock recovers and management improves. I hope that is not some insane fantasy...

Cathie Wood of Ark Invest did a video with CNBC yesterday going over her investments and made a big push on Teledoc. One of the key reasons behind it was the tie up with Livongo and the data that they will be throwing off and the extreme value that it creates for the medical sphere.

Is there a company that is gaining huge wads of data on a variety of diseases through their testing facilities that could also be throwing up extreme value? Any answers would be gratefully received.

The MS trial was supposed to start in January as I recall from previous interviews. That has not materialised. There is a take it or leave it attitude towards investors.

Investors have decided to leave it. Hope it changes investors deserve more... like timescales given and honoured. Or minimum when failed... communication provided.

Guys are getting plenty of time to load up for the contracts that now get released, on the back of the news. They probably have no idea of the other revenue streams that this company are hitting in the months ahead.